Reviva Pharmaceuticals Holdings, Inc.RVPHNASDAQ
Loading
R&D Expense Growth Under PressureDecelerating
Percentile Rank17
Studio
Year-over-Year Change

Year-over-year research & development expense growth

Percentile
P17
Within normal range
vs 3Y Ago
0x
Contraction
Streak
3 yr
Consecutive declineDecelerating
PeriodValue
2024-27.09%
202365.82%
2022290.55%
20211543.78%
202050.78%
2019-79.31%
20180.00%